Literature DB >> 16981300

Sipuleucel-T shows partial advantage in prostate cancer.

Paula Gould.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16981300     DOI： 10.1016/s1470-2045(06)70846-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Immunotherapy for solid tumors--a review for surgeons.

Authors:  Abdul Saied; Venu G Pillarisetty; Steven C Katz
Journal:  J Surg Res       Date:  2013-12-25       Impact factor: 2.192

Review 2.  Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics.

Authors:  Ilene Le; Subramanian Dhandayuthapani; Jessica Chacon; Anna M Eiring; Shrikanth S Gadad
Journal:  Vaccines (Basel)       Date:  2022-05-21

3.  Cancer immunotherapy in clinical practice -- the past, present, and future.

Authors:  Gaurav Goel; Weijing Sun
Journal:  Chin J Cancer       Date:  2014-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.